Abstract
This 1-day meeting was held at the Austria Trend Savoyen Hotel, Vienna, Austria. The morning session consisted of a series of presentations by experts in the field of cystinosis. Prof Katharina Hohenfellner gave an overview of nephropathic cystinosis (NC) and provided her own experience of a multidisciplinary patient follow-up. Dr Alexey Tsygin provided his long-term experience of treatment with cysteamine and highlighted the importance of treating early and the role of cysteamine in treating and preventing long-term complications of cystinosis. Dr Roser Torra presented the findings of the T-CiS.bcn project, which aimed to develop a transition plan from paediatric to adult care through a multidisciplinary team. Dr Rachel Bishop provided an overview of the ocular manifestations of cystinosis followed by a presentation on the most recent data with gel-like Cystadrops® from Dr Hong Liang.
The key themes from the morning sessions were:
With the development of specific treatment for cystinosis, the disease paradigm has shifted from a paediatric illness where patients suffer end-stage renal disease (ESRD) by 10 years of age to a longerterm multisystemic illness with extra-renal complications
Earlier treatment of NC with cysteamine can delay both the renal and extra-renal manifestations of the disease
There are difficulties in transitioning from paediatric to adult care and this can lead to reduced treatment adherence; a multidisciplinary team may help to smooth the transition
Reference24 articles.
1. Emma F et al. Nephropathic cystinosis: an international consensus document. Nephrol Dial Transplant. 2014;29 Suppl 4:iv87-94.
2. European Medicines Agency. Cystagon Summary of Product Characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000125/WC500037764.pdf. Last accessed: 26 January 2017.
3. Nesterova G et al., “Cystinosis,” Pagon RA, et al. (eds.), GeneReviews® (1993–2017). Available at: https://www.ncbi.nlm.nih.gov/books/NBK1116/. Last accessed: 26 January 2017.
4. Gahl WA et al. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med. 2007;147(4):242-50.
5. Nesterova G et al. Cystinosis: the evolution of a treatable disease. Pediatr Nephrol. 2013;28(1):51-9.